– Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – – Also at CROI: New PURPOSE 1 Data Showcasing Preference for ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief ...

Results from studies have shown the overwhelming efficacy of twice-yearly injections of Lenacapavir (LEN) in the prevention of HIV infections compared to standard oral preventive HIV medicines, known ...

The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Tuesday, Gilead Sciences Inc (NASDAQ:GILD) reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. Sales increased 6% year over year to $7.57 billion, beating the consensus ...

Share on Pinterest The WHO has recommended the use of lenacapavir to help prevent HIV. Jakub Porzycki/NurPhoto via Getty Images The human immunodeficiency virus (HIV), which can lead to acquired ...

Use of lenacapavir in people with HIV who are heavily treatment-experienced resulted in high levels of virologic suppression, according to two small studies presented at the Infectious Disease Week ...